MedImmune Infinity Collaboration Agreement of August 25, 2006
The Infinity MedImmune alliance was filed yesterday.
I think this will be one of the interesting deals of 2006. From Infinity's website on November 3, 2006: “In August, 2006, Infinity and MedImmune announced that they have entered into an agreement to jointly develop and commercialize novel small molecule cancer drugs targeting Heat Shock Protein 90 (Hsp90) and the Hedgehog cell-signaling pathway. The collaboration will focus on IPI-504, Infinity’s lead Hsp90 inhibitor in Phase I clinical trials, as well as next-generation oral versions of IPI-504 and a series of preclinical molecules targeting the Hedgehog pathway, including IPI-609.
Under the terms of the agreement, MedImmune and Infinity will share equally all costs and profits from the development and commercialization of any future products. MedImmune will provide Infinity a one-time upfront payment of $70 million for co-exclusive, shared rights to the Hsp90 and Hedgehog pathway product development programs. In addition, Infinity could receive up to an additional $430 million in milestone payments related to the companies’ achieving certain late-stage clinical development and sales targets for any future products resulting from the collaboration.
For each of the Hsp90 and Hedgehog pathway programs, Infinity will retain primary responsibility for discovery, preclinical development and translational clinical development of products through proof-of-concept in humans. MedImmune and Infinity will jointly conduct clinical development through first product approval. MedImmune will lead worldwide regulatory strategy as well as sales and marketing of resulting products; Infinity retains an option to co-promote any future products in the United States, contributing up to 35 percent of the total promotional effort.”
See the full text here: MedImmune Infinity Collaboration Agreement of August 25, 2006.
I think this will be one of the interesting deals of 2006. From Infinity's website on November 3, 2006: “In August, 2006, Infinity and MedImmune announced that they have entered into an agreement to jointly develop and commercialize novel small molecule cancer drugs targeting Heat Shock Protein 90 (Hsp90) and the Hedgehog cell-signaling pathway. The collaboration will focus on IPI-504, Infinity’s lead Hsp90 inhibitor in Phase I clinical trials, as well as next-generation oral versions of IPI-504 and a series of preclinical molecules targeting the Hedgehog pathway, including IPI-609.
Under the terms of the agreement, MedImmune and Infinity will share equally all costs and profits from the development and commercialization of any future products. MedImmune will provide Infinity a one-time upfront payment of $70 million for co-exclusive, shared rights to the Hsp90 and Hedgehog pathway product development programs. In addition, Infinity could receive up to an additional $430 million in milestone payments related to the companies’ achieving certain late-stage clinical development and sales targets for any future products resulting from the collaboration.
For each of the Hsp90 and Hedgehog pathway programs, Infinity will retain primary responsibility for discovery, preclinical development and translational clinical development of products through proof-of-concept in humans. MedImmune and Infinity will jointly conduct clinical development through first product approval. MedImmune will lead worldwide regulatory strategy as well as sales and marketing of resulting products; Infinity retains an option to co-promote any future products in the United States, contributing up to 35 percent of the total promotional effort.”
See the full text here: MedImmune Infinity Collaboration Agreement of August 25, 2006.
Tags:
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home